thyTregs™

thyTreg® in the clinic

Off-the-shelf thyTregs® promote and preserve immune homeostasis by enforcing peripheral tolerance. By damping pathogenic effector responses and reestablishing immune homeostasis, thyTregs® have the potential to prevent and/or treat:

  • Solid-organ allograft rejection.
  • GVHD.
  • Autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, Crohn’s disease, thyroiditis, and psoriasis.
  • Immune-mediated neurodegenerative disorders.
  • In gene therapy, thyTregs® may reduce anti-vector immunity and toxicity, helping maintain transgene expression.

thyTreg®, off-the-shelf lead product

thyTregs® combine best-in-class function with low immunogenicity

  • Donor-derived
  • Non-engineered
  • Cryopreserved polyclonal thyTregs®

Key attributes

Quality
  • Viability: 93.25%; Treg purity (CD25⁺FOXP3⁺) 92.89% at day 7.
  • Phenotype: naïve-like; ↑ CD25, ↑ FOXP3, ↑ HELIOS

Bernaldo-de-Quirós E, et al. Front Immunol. 2022;13:893576.

Potency
  • Strong suppression of unmatched immune cell proliferation/activation.
  • ↑ IL-10, TGF-β; ↓ IFN-γ, IL-17A.

Suppressive capacity (% inhibition of CD4/CD8 proliferation)

Secreted cytokines

Bernaldo-de-Quirós E, et al. Front Immunol. 2022;13:893576.

Durability
  • Hypoimmunogenic: ↓ CD80/CD86, ↓ HLA-II; ↑ CTLA-4; ↑ IL-10, TGF-β support tolerance.
  • Long telomeres → higher replicative potential and in vivo survival.
Stability
  • High, stable FOXP3 TSDR demethylation.
  • Phenotype and potency maintained under pro-inflammatory cytokines.

Stability in proinflammatory conditions

Bernaldo-de-Quirós E, et al. Front Immunol. 2022;13:893576.

Scale
  • Target 1 trillion cells per thymus (500 -1,000 doses at 1 billion cells/dose).